| Title |
A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action
|
|---|---|
| Published in |
Psychopharmacology, October 1992
|
| DOI | 10.1007/bf02245475 |
| Pubmed ID | |
| Authors |
Gerard J. Marek, Christopher J. McDougle, Lawrence H. Price, Lewis S. Seiden |
| Abstract |
Trazodone is an atypical antidepressant drug that is commonly referred to as a serotonin (5-hydroxytryptamine; 5-HT) uptake inhibitor. However, the most potent pharmacological effect of trazodone appears to be antagonist action at 5-HT2/1C receptors. This is in contrast to fluoxetine, for which inhibition of 5-HT uptake is the most potent pharmacological action. The effects of trazodone and fluoxetine on several antidepressant drug screens are mediated by antagonist action at 5-HT2 receptors and inhibition of 5-HT uptake, respectively. While fluoxetine is an effective agent for the treatment of major depression, obsessive-compulsive disorder (OCD) and panic disorder, trazodone does not appear to be effective in the treatment of OCD and panic disorder. In addition, trazodone and fluoxetine differ in humans with respect to their effects on sleep and weight. Taken together, the preclinical and clinical data suggest that trazodone acts as an antidepressant via antagonist action at 5-HT2/1C receptors, while fluoxetine likely acts as an antidepressant via inhibition of 5-HT uptake. |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 43 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 18% |
| Student > Master | 5 | 11% |
| Researcher | 4 | 9% |
| Student > Doctoral Student | 3 | 7% |
| Student > Postgraduate | 3 | 7% |
| Other | 10 | 22% |
| Unknown | 12 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 29% |
| Agricultural and Biological Sciences | 6 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 11 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2020.
All research outputs
#4,695,994
of 22,786,087 outputs
Outputs from Psychopharmacology
#1,231
of 5,346 outputs
Outputs of similar age
#2,181
of 19,041 outputs
Outputs of similar age from Psychopharmacology
#6
of 17 outputs
Altmetric has tracked 22,786,087 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,346 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 19,041 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.